Alexandria to
lead mission-critical panel on immunology and inflammation as a
cornerstone of treating human disease tomorrow at the 2024 Galien
Forum USA at the Alexandria
Center® for Life Science – New York City
PASADENA, Calif., Nov. 6, 2024
/PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE),
the first, preeminent, longest-tenured and pioneering owner,
operator and developer of collaborative mega campuses in AAA
life science innovation cluster locations, continues to leverage
its position at the vanguard and heart of the $5 trillion secularly growing life science
industry to foster the development of new therapies and cures for
the 10,000 diseases known to humankind, of which less than 10% are
currently addressable with treatments. With $4.5 trillion in U.S. healthcare spending in
2022, the majority of which is attributed to hospital and physician
services, the opportunity to reduce the economic burden on the
country and better manage disease for patients through the
development of new innovative medicines remains immense. Driven by
decades of scientific discovery, the U.S. Food and Drug
Administration (FDA) this year has approved 38 novel small molecule
and biologic therapies, as well as six new innovative medicines,
which include novel vaccines and next-generation modalities such as
cell, gene and mRNA-based therapies. Alexandria tenants are responsible for five of
these six innovative medicines, reflecting the cutting-edge science
taking place within the company's Labspace® facilities
and the high quality of the company's client base. Innovative
medicines continue to gain momentum with a 286% increase in
approvals by the FDA in this class between the 2017–2020 and
2021–YTD 2024 periods.
"As innovative medicine approvals by the FDA have ramped up over
the past several years, the promise of next-generation medicine is
being realized in key areas of unmet need, including oncology,
neurodegenerative and psychiatric disorders and diseases of the
immune system, which means expanded treatment options and enhanced
quality of life for patients," said Joel S. Marcus, executive chairman and founder
of Alexandria Real Estate Equities, Inc. and Alexandria Venture
Investments. "Innovation in medicine is the only effective path to
solving the over 90% of diseases that currently have no treatments
and to reducing long-term costs associated with the healthcare
system. New medicines delivered to patients and early detection of
costly diseases, like Alzheimer's or cancer, mean fewer visits to
the hospital and fewer treatments over the long term. At
Alexandria, we are working to
ensure that the life science industry can maintain its
collaborative science-driven advantage as one of the world's most
innovative, impactful and critical industries, and one that is
vastly improving health and well-being."
Alexandria has a remarkable
track record of partnering with trailblazing life science companies
to enable the development of life-changing and lifesaving
treatments and cures. Since 2013, Alexandria tenants have developed or
commercialized half the novel FDA-approved therapies, and so far in
2024, they have been responsible for over 80% of the FDA approvals
for innovative medicines. Many of these approvals are
first-of-their-kind medicines. Notably, Moderna, with which
Alexandria began its strategic
relationship in 2012, received approval for a respiratory syncytial
virus (RSV) vaccine. Moderna's novel RSV vaccine validates the
potential of its paradigm-shifting mRNA technology to address
multiple diseases, and it is also the first mRNA vaccine to be
approved for a disease other than COVID-19. Included among the
Alexandria tenants harnessing the
immune system to treat cancer is Iovance Biotherapeutics, which
received FDA approval for the first tumor-infiltrating lymphocyte
cell therapy to treat advanced melanoma. Alexandria has been providing mission-critical
real estate to Iovance in the San
Francisco Bay Area since early 2022.
The field of immunology and inflammation has emerged as
fundamental to how we approach a wide array of human diseases.
Recent breakthroughs in our understanding of the immune system are
leading to revolutionary therapies and opening new frontiers in
medical science. Moreover, immunology is predicted to become the
second-largest area of biopharmaceutical spend by 2028, behind
oncology, and the global immunology market is expected to more than
double from nearly $103 billion in
2024 to $257 billion by 2032.
In light of the paramount importance of this burgeoning field,
Alexandria is leading a
mission-critical panel titled "Immunology & Inflammation – A
Cornerstone of Treating Human Disease" tomorrow, November 7, 2024, at the 2024 Galien Forum
USA at the Alexandria
Center® for Life Science – New
York City. Co-moderated by Mr. Marcus and Lynne Zydowsky, PhD, chief of science of
Alexandria, the pivotal discussion
will feature pioneers in immunology who will delve into the latest
advances, current challenges and future opportunities for
harnessing the immune system to combat chronic and inflammatory
disorders. Alexandria's panel will
also explore how immunological and anti-inflammatory approaches are
reshaping our understanding of disease mechanisms and opening new
opportunities for treatment. These latest developments — from
engineered cell therapies to novel immunomodulatory drugs — hold
the promise to transform the treatment landscape for millions of
patients worldwide.
About Alexandria Real Estate Equities, Inc.
Alexandria
Real Estate Equities, Inc. (NYSE: ARE), an S&P
500® company, is a best-in-class, mission-driven
life science REIT making a positive and lasting impact on the
world. As the pioneer of the life science real estate niche with
our founding in 1994, Alexandria
is the preeminent and longest-tenured owner, operator and developer
of collaborative mega campuses in AAA life science innovation
cluster locations, including Greater
Boston, the San Francisco Bay
Area, San Diego,
Seattle, Maryland, Research Triangle and New York City. As of September 30, 2024, Alexandria has a total market capitalization
of $33.1 billion and an asset base in
North America that includes 41.8
million RSF of operating properties, 5.3 million RSF of Class A/A+
properties undergoing construction, and one committed near-term
project expected to commence construction in the next two years.
Alexandria has a longstanding and
proven track record of developing Class A/A+ properties clustered
in mega campuses that provide our innovative tenants with highly
dynamic and collaborative environments that enhance their ability
to successfully recruit and retain world-class talent and inspire
productivity, efficiency, creativity and success. Alexandria also provides strategic capital to
transformative life science companies through our venture capital
platform. We believe our unique business model and diligent
underwriting ensure a high-quality and diverse tenant base that
results in higher occupancy levels, longer lease terms, higher
rental income, higher returns and greater long-term asset value.
For more information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements include, without limitation,
statements regarding Alexandria's
impact on the life science industry, on its tenants' business and
pursuit of novel treatment and cures and on human health and
well-being. These forward-looking statements are based on
Alexandria's present intent,
beliefs or expectations, but forward-looking statements are not
guaranteed to occur and may not occur. Actual results may differ
materially from those contained in or implied by Alexandria's forward-looking statements as a
result of a variety of factors, including, without limitation, the
risks and uncertainties detailed in its filings with the Securities
and Exchange Commission. All forward-looking statements are made as
of the date of this press release, and Alexandria assumes no obligation to update
this information. For more discussion relating to risks and
uncertainties that could cause actual results to differ materially
from those anticipated in Alexandria's forward-looking statements, and
risks and uncertainties to Alexandria's business in general, please refer
to Alexandria's filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and any subsequently filed quarterly
reports on Form 10-Q.
CONTACT: Joel S. Marcus, Executive Chairman & Founder,
(626) 578-9693, jmarcus@are.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-enables-the-discovery-development-and-delivery-of-new-innovative-medicines-that-are-key-to-addressing-significant-unmet-medical-need-302296686.html
SOURCE Alexandria Real Estate Equities, Inc.